ENPP2 and idiopathic pulmonary fibrosis: New agents targeting the various stages in the pathogenesis (Figure 3) of disease are under study in IPF and include calpain inhibitors, which are calcium‐dependent cysteine proteases that influence cell signalling; metformin, which activates AMP‐activated protein kinase facilitating deactivation and apoptosis of myofibroblasts potentially reversing established fibrosis; and GLPG1690, a novel inhibitor of autotaxin, an enzyme involved in lysophosphatidic acid (LPA) production.